Bone: Does anti-sclerostin therapy promote inflammation in rheumatoid arthritis?

Abstract

One of the most promising new approaches currently in clinical trials for postmenopausal osteoporosis is the promotion of bone formation by antibodies directed against the Wnt inhibitor, sclerostin. A new study by Wehmeyer and colleagues suggests that this approach might have a pro-inflammatory effect in patients with tumour necrosis factor (TNF)-dependent rheumatoid arthritis.